RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

被引：0
|
作者：
Ernest Nadal
Hidehito Horinouchi
Jin-Yuan Shih
Kazuhiko Nakagawa
Martin Reck
Edward B. Garon
Yu-Feng Wei
Jens Kollmeier
Bente Frimodt-Moller
Emily Barrett
Olga Lipkovich
Carla Visseren-Grul
Silvia Novello
机构：
[1] Catalan Institute of Oncology,Faculty of Medicine
[2] IDIBELL,Department of Oncology
[3] L’Hospitalet,undefined
[4] National Cancer Center Hospital,undefined
[5] National Taiwan University Hospital,undefined
[6] Kindai University,undefined
[7] LungenClinic,undefined
[8] Airway Research Center North,undefined
[9] German Center for Lung Research,undefined
[10] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network,undefined
[11] E-Da Cancer Hospital,undefined
[12] I-Shou University,undefined
[13] Helios Klinikum Emil von Behring,undefined
[14] Eli Lilly and Company,undefined
[15] Eli Lilly and Company,undefined
[16] Eli Lilly and Company,undefined
[17] Lilly Oncology,undefined
[18] University of Turin,undefined
[19] A.O.U. San Luigi Gonzaga,undefined
来源：
Drug Safety | 2022年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：45 / 64
页数：19
相关论文
共 50 条
  • [31] INDIRECT COMPARISON OF THE EFFICACY OF ERLOTINIB VERSUS PEMETREXED PLUS CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS
    Pereira, C.
    Sanches, M.
    Loff, J. F.
    VALUE IN HEALTH, 2012, 15 (07) : A411 - A412
  • [32] OVERCOMING ERLOTINIB RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER CELLS BY TARGETING SURVIVIN
    Okamoto, K.
    Okamoto, I.
    Hatashita, E.
    Kuwata, K.
    Yamaguchi, H.
    Kita, A.
    Yamanaka, K.
    Ono, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 85 - 85
  • [33] Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer
    Sakata, Yoshihiko
    Kawamura, Kodai
    Shingu, Naoki
    Ichikado, Kazuya
    LUNG CANCER, 2016, 99 : 120 - 122
  • [34] Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer
    Ochi, Nobuaki
    Isozaki, Hideko
    Takeyama, Masami
    Singer, Jack W.
    Yamane, Hiromichi
    Honda, Yoshihiro
    Kiura, Katsuyuki
    Takigawa, Nagio
    CANCER RESEARCH, 2016, 76
  • [35] Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial
    de Marinis, Filippo
    Vergnenegre, Alain
    Passaro, Antonio
    Dubos-Arvis, Catherine
    Carcereny, Enric
    Drozdowskyj, Ana
    Zeaiter, Ali
    Perez-Moreno, Pablo
    Rosell, Rafael
    FUTURE ONCOLOGY, 2015, 11 (03) : 421 - 429
  • [36] Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3303 - 3306
  • [37] Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
    Zhang, Shu
    Mao, Xiao-dong
    Wang, Hai-tao
    Cai, Feng
    Xu, Jing
    BMJ OPEN, 2016, 6 (06):
  • [38] Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer
    Scagliotti, Giorgio V.
    Novello, Silvia
    Schiller, Joan H.
    Hirsh, Vera
    Sequist, Lecia V.
    Soria, Jean-Charles
    von Pawel, Joachim
    Schwartz, Brian
    Von Roemeling, Reinhard
    Sandler, Alan B.
    CLINICAL LUNG CANCER, 2012, 13 (05) : 391 - 395
  • [39] PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB
    Ashizawa, Nobuyuki
    Motoshima, Kohei
    Nakamura, Yoichi
    Sano, Kazumi
    Ikegami, Yoji
    Ikeda, Takaya
    MizoguchE, Kosuke
    Takemoto, Shinnosuke
    Fukuda, Minoru
    Nagashima, Seiji
    Iida, Tetsuya
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S486 - S486
  • [40] PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB
    Fukushima, A.
    Motoshima, K.
    Shimada, M.
    Kitazaki, T.
    Fukuda, M.
    Hashiguchi, K.
    Nagashima, S.
    Sano, K.
    Nakamura, Y.
    Kohno, S.
    RESPIROLOGY, 2012, 17 : 81 - 81
12345